Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

Fig. 1

HbA1c (a) and FPG (b) at baseline and Week 24 ±CVD or lipid-lowering therapy. Data presented represent mean (standard deviation). P < 0.05 between patients treated with lipid-lowering therapy versus not treated for HbA1c at baseline and change to Week 24, differences were not significant in FPG

Back to article page